The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...

Earlier this month, the FDA removed Lilly’s popular GLP-1 drug tirzepatide from its shortage list after confirming with Lilly ...

Drugs​ like Mounjaro and Ozempic, which many use for weight loss,​​ may also help patients suffering from addiction, according to a new study.

You’ve probably heard of the semaglutide brand names Ozempic®, Wegovy, and Rybelsus. You may have even heard about affordable options like compounded semaglutide.

As an investor in Eli Lilly stock, I'm encouraged by the company's forward thinking. Not only is management making moves to ...

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

"These are not case-specific issues," the plaintiffs contended. "The marketing was national in scale and magnitude, and ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

“ (Weight loss medications) can help, for sure, but exercise and getting enough protein to make sure you aren’t losing muscle ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven major gains in recent times. And that's the company's weight loss drugs.